GILD · News · 20261104N
T-Cell Engager Pipeline Collaboration
GILEAD SCIENCES, INC. · 2026-11-04 · Importance 34 · Surprise 42 · In source text
Vir Biotechnology reported a collaboration and license agreement with Gilead to discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates. The agreement adds candidates to Gilead’s development pipeline through a partner collaboration. The digest provides no target indications, development timelines, or commercial terms for the Gilead agreement.
Key facts
- Gilead Sciences entered a collaboration and license agreement with Vir Biotechnology to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates. source
- Gilead Sciences provided $90 million in upfront consideration for its collaboration with Vir Biotechnology. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.2% | Gilead Sciences provided $90 million in upfront consideration for its collaboration with Vir Biotechnology. |